Oxford Biomedica PLC Director/PDMR Shareholding (3011Q)
28 November 2016 - 9:06PM
UK Regulatory
TIDMOXB
RNS Number : 3011Q
Oxford Biomedica PLC
28 November 2016
Director Dealings / Market Share Purchase
Oxford, UK - 28 November 2016: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the
Group, on Friday, 25 November 2016, acquired ordinary shares in the
Group as set out below, under the market share purchase agreement
outlined in the Group's announcement on 15 December 2015.
Under the market share purchase agreement, one-third of Dr
Tallarigo's fees as Chairman, after tax, are to be used to purchase
shares in Oxford BioMedica PLC on a monthly basis at the prevailing
market price.
Interest after
purchase
----------- --------- ---------- ---------------- ----------------------------
Director Title Price Number of Number % of total
/ PDMR per share Ordinary Shares of Ordinary issued
(p) acquired Shares share capital
----------- --------- ---------- ---------------- ------------ --------------
Dr Lorenzo
Tallarigo Chairman 3.5p 75,417 1,588,116 0.05%
----------- --------- ---------- ---------------- ------------ --------------
The issued share capital of the Group is 3,087,953,461 ordinary
1p shares.
-Ends-
For further information,
please contact:
Oxford BioMedica plc: Tel: +44 (0)1865
John Dawson, Chief Executive 783 000
Officer
Tim Watts, Chief Financial
Officer
Financial and corporate communications Tel: +44 (0)20 3709
enquiries: 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew
Neal/Chris Welsh/Laura Thornton
Notes for editors
About Oxford BioMedica(R)
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ) through which the Group develops in vivo and ex
vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, GSK, and Immune
Design, through which it has long-term economic interests in other
potential gene and cell therapy products. Oxford BioMedica is based
across several locations in Oxfordshire, UK and employs more than
250 people. Further information is available at
www.oxfordbiomedica.co.uk.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHBGBDBXGDBGLI
(END) Dow Jones Newswires
November 28, 2016 05:06 ET (10:06 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024